Voyager Acquisition's (VACH) planned merger target Veraxa Biotech on Monday said it entered a co-discovery alliance with OmniAb (OABI) to develop a bispecific antibody drug conjugate targeting solid tumors.
Veraxa will lead the program, using OmniAb's transgenic antibody discovery platform to identify antibody leads for two cancer targets, the company said.
The resulting drug candidate will be jointly owned, and both parties will share any future revenues from development, licensing, or commercialization.
Price: 10.30, Change: +0.02, Percent Change: +0.17
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.